Valbenazine granted breakthrough drug status for treating tardive dyskinesia

Expert Opinion on Investigational Drugs

Volumn 24, Issue 6, 2015, Pages 737-742

  Müller, Thomas ^a  

^a St Joseph Hospital Berlin Weissensee   (Germany)

Author keywords

Dyskinesia; Tardive dyskinesia; Tetrabenazine; Tic; Tourette syndrome; Valbenazine

Indexed keywords

AMANTADINE; AMPHETAMINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; DIHYDROTETRABENAZINE; DRUG METABOLITE; ETIRACETAM; METHAMPHETAMINE; PIRACETAM; PROPRANOLOL; PYRIDOXINE; RESERPINE; TETRABENAZINE; VALBENAZINE; ANTIPARKINSON AGENT; NEUROLEPTIC AGENT; VALINE;

CLINICAL RESEARCH; DISEASE SEVERITY; DRUG EFFICACY; GINKGO BILOBA; HUMAN; INVOLUNTARY MOVEMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHENOMENOLOGY; REVIEW; RISK FACTOR; TARDIVE DYSKINESIA; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; DRUG APPROVAL; DYSKINESIA, DRUG-INDUCED; FOOD AND DRUG ADMINISTRATION; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; UNITED STATES;

ANTI-DYSKINESIA AGENTS; ANTIPSYCHOTIC AGENTS; DRUG APPROVAL; DYSKINESIA, DRUG-INDUCED; HUMANS; SEVERITY OF ILLNESS INDEX; TETRABENAZINE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VALINE;

EID: 84929311368     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2015.1029573     Document Type: Review

References (32)

1. Cloud LJ, Zutshi D, Factor SA. Tardive dyskinesia: therapeutic options for an increasingly common disorder. Neurotherapeutics 2014;11(1):166-76
2. Müller T, Russ H. Levodopa, motor fluctuations and dyskinesia in Parkinson's disease. Expert Opin Pharmacother 2006;7(13):1715-30
3. Chen JJ, Ondo WG, Dashtipour K, Swope DM. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Clin Ther 2012;34(7):1487-504
4. Ehrenpreis ED, Deepak P, Sifuentes H, et al. The metoclopramide black box warning for tardive dyskinesia: effect on clinical practice, adverse event reporting, and prescription drug lawsuits. Am J Gastroenterol 2013;108(6):866-72
5. Fernandez HH, Friedman JH. Classification and treatment of tardive syndromes. Neurologist 2003;9(1):16-27
6. Hazari N, Kate N, Grover S. Clozapine and tardive movement disorders: a review. Asian J Psychiatr 2013;6(6):439-51
7. Wojcik JD, Falk WE, Fink JS, et al. A review of 32 cases of tardive dystonia. Am J Psychiatry 1991;148(8):1055-9
8. Merrill RM, Lyon JL, Matiaco PM. Tardive and spontaneous dyskinesia incidence in the general population. BMC Psychiatry 2013;13:152-7
9. Jankovic J, Clarence-Smith K. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Rev Neurother 2011;11(11):1509-23
10. Kimiagar I, Dobronevsky E, Prokhorov T, et al. Rapid improvement of tardive dyskinesia with tetrabenazine, clonazepam and clozapine combined: a naturalistic long-term follow-up study. J Neurol 2012;259(4):660-4
11. Rana AQ, Chaudry ZM, Blanchet PJ. New and emerging treatments for symptomatic tardive dyskinesia. Drug Des Devel Ther 2013;7:1329-40
12. Zai CC, Tiwari AK, Mazzoco M, et al. Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia. J Psychiatr Res 2013;47(11):1760-5
13. Koeppe RA, Frey KA, Kuhl DE, Kilbourn MR. Assessment of extrastriatal vesicular monoamine transporter binding site density using stereoisomers of [11C] dihydrotetrabenazine. J Cereb Blood Flow Metab 1999;19(12):1376-84
14. Yao Z, Wei X, Wu X, et al. Preparation and evaluation of tetrabenazine enantiomers and all eight stereoisomers of dihydrotetrabenazine as VMAT2 inhibitors. Eur J Med Chem 2011;46(5):1841-8
15. LeWitt PA. Tardive dyskinesia caused by tetrabenazine. Clin Neuropharmacol 2013;36(3):92-3
16. Kilbourn M, Lee L, Vander BT, et al. Binding of alpha-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific. Eur J Pharmacol 1995;278(3):249-52
17. Kilbourn MR, Lee LC, Heeg MJ, Jewett DM. Absolute configuration of (+)- alpha-dihydrotetrabenazine, an active metabolite of tetrabenazine. Chirality 1997;9(1):59-62
18. Liu C, Chen Z, Li X, et al. (+)-9-Benzyloxy-alpha-dihydrotetrabenazine as an important intermediate for the VMAT2 imaging agents: absolute configuration and chiral recognition. Chirality 2013;25(4):215-23
19. Paek SM, Kim NJ, Shin D, et al. A concise total synthesis of (+)- tetrabenazine and (+)-alphadihydrotetrabenazine. Chemistry 2010;16(15):4623-8
20. O'Brien CF, Jiminez R, Hauser RA, et al. Kinect 2: NBI-98854 treatment of moderate to severe tardive dyskinesia. Mov Disord 2014;29(Suppl 1):829
21. Ondo WG, Hanna PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry 1999;156(8):1279-81
22. Poulopoulos M, Hajjar M. Posttraumatic tics and tetrabenazine treatment: a blinded video assessment. BMJ Case Rep 2013;2013
23. Fernandez HH, Krupp B, Friedman JH. The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14-year follow-up. Neurology 2001;56(6):805-7
24. Nunes EJ, Randall PA, Hart EE, et al. Effort-related motivational effects of the VMAT-2 inhibitor tetrabenazine: implications for animal models of the motivational symptoms of depression. J Neurosci 2013;33(49):19120-30
25. Vaughan RA, Foster JD. Mechanisms of dopamine transporter regulation in normal and disease states. Trends Pharmacol Sci 2013;34(9):489-96
26. Remington G, Kapur S, Foussias G, et al. Tetrabenazine augmentation in treatment-resistant schizophrenia: a 12-week, double-blind, placebo-controlled trial. J Clin Psychopharmacol 2012;32(1):95-9
27. Dorsey ER, Brocht AF, Nichols PE, et al. Depressed mood and suicidality in individuals exposed to tetrabenazine in a large Huntington disease observational study. J Huntingtons Dis 2013;2(4):509-15
28. Dorsey R, Biglan K, Eberly S, et al. Use of tetrabenazine in Huntington disease patients on antidepressants or with advanced disease: results from the TETRA-HD study. PLoS Curr 2011;3:RRN1283
29. Shen V, Clarence-Smith K, Hunter C, Jankovic J. Safety and efficacy of tetrabenazine and use of concomitant medications during long-term, open-label treatment of chorea associated with Huntington's and other diseases. Tremor Other Hyperkinet Mov (N Y) 2013;3
30. Goetz CG, Damier P, Hicking C, et al. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov Disord 2007;22(2):179-86
31. Rascol O, Fox S, Gasparini F, et al. Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopainduced dyskinesias. Parkinsonism Relat Disord 2014;20(9):947-56
32. Lidstone SC. Great expectations: the placebo effect in Parkinson's disease. Handb Exp Pharmacol 2014;225:139-47